Why does compounded tirzepatide exist at all?
Tirzepatide is the active ingredient in Eli Lilly’s branded drugs Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight management). Neither is a compounded product — they are FDA-approved drugs manufactured under strict pharmaceutical controls.
Compounded tirzepatide entered the picture because the branded products experienced documented supply shortages beginning in 2022. Under U.S. federal law (21 U.S.C. §353a), licensed 503A compounding pharmacies are permitted to compound drugs that are on the FDA’s Active Drug Shortage list when a valid prescription from a licensed clinician is present. The shortage created the legal window that allowed compounding pharmacies to prepare tirzepatide at scale.
It is important to be clear: compounded tirzepatide is not FDA-approved and is not manufactured by Eli Lilly. It is prepared by licensed 503A compounding pharmacies in the USA from bulk drug substances. No implication of FDA approval should be drawn from the availability of compounded formulations.
What does the FDA shortage status actually control for compounded tirzepatide?
The FDA maintains an Active Drug Shortages database and makes formal determinations about whether a shortage exists. That determination is the legal hinge on which compounding access swings:
- Shortage active: 503A compounding pharmacies may legally compound tirzepatide for patients with a prescription. Telehealth clinics and brick-and-mortar practices can route patients through this channel.
- Shortage resolved: The legal basis for compounding under the shortage exemption evaporates. 503A pharmacies must stop general compounding of tirzepatide. Patients who were receiving compounded doses need a transition plan.
- Shortage status changes over time: The FDA has updated tirzepatide shortage status multiple times. A shortage that was resolved in one dosage form may still be active in another. The status is not binary and not static.
The FDA’s shortage determination is separate from court decisions about compounding. Litigation over GLP-1 compounding rules has produced injunctions that temporarily paused enforcement in some circumstances, but these are legal proceedings that can reverse. Relying on injunctions as a long-term access plan is risky.
There is no permanent ban on compounded tirzepatide — its legality is shortage-status-dependent, swinging on the FDA’s determination.
What does “compounded tirzepatide ban” actually mean?
The phrase “compounded tirzepatide ban” is commonly used but somewhat misleading. There is no permanent regulatory ban on tirzepatide as a compound. What exists is a shortage-dependent access framework:
- No shortage = no compounding exemption = no legal compounding at 503A pharmacies for general dispensing.
- Active shortage = compounding exemption applies = legal compounding with a clinician’s prescription.
When patients see headlines saying compounded tirzepatide is “banned,” they are typically reading about the FDA declaring the shortage resolved (or partially resolved for certain dosage strengths), which removes the shortage exemption and returns compounding to its default prohibited status for this drug.
The distinction matters because it affects what comes next. A shortage resolution is not necessarily permanent — if supply disruptions return, the shortage can be reinstated. And the legal landscape around compounding, including active litigation, continues to evolve.
What does 503A versus 503B mean for you?
Not all compounding pharmacies operate the same way. Understanding the distinction helps you evaluate what you are actually receiving:
- 503A pharmacies are traditional compounding pharmacies that prepare medications for specific patients under individual prescriptions. They operate under state pharmacy board oversight plus applicable FDA rules. PepScribe works exclusively with licensed 503A pharmacies in the USA.
- 503B outsourcing facilities operate under more intensive FDA oversight and can produce larger batches without patient- specific prescriptions. The shortage compounding rules apply differently to 503B facilities.
- Unregulated sources— overseas vendors, “research chemical” suppliers, gray-market compounders — carry serious risks around purity, sterility, and accurate dosing. PepScribe does not source from or work with any unregulated supply chain. No hidden overseas supply chain.
What should you do if your compounded tirzepatide access changes?
If you are currently on compounded tirzepatide and the legal landscape shifts, do not stop abruptly without medical guidance. GLP-1 receptor agonists affect appetite regulation, gut motility, and insulin signaling. Changes to dosing or discontinuation should be managed with a clinician who knows your case.
Clinician-supervised options depending on your situation may include transitioning to a branded product if insurance coverage or pricing allows, adjusting dose, or discussing other approaches within legal channels. The right path depends on why you were on tirzepatide in the first place and what your clinical goals are.
PepScribe connects patients with licensed clinicians who review intake on a case-by-case basis. If you are navigating a change in tirzepatide access, the best first step is a clinician conversation — not a decision based on headlines.
Frequently asked questions
Is compounded tirzepatide going away?
Compounded tirzepatide availability is tied to the FDA's shortage determination for branded tirzepatide products. When the FDA officially declares a shortage resolved, 503A compounding pharmacies are no longer permitted to compound it for general dispensing. The shortage status has fluctuated, and patients should consult a licensed clinician for the most current access pathway.
Is compounded tirzepatide legal?
During an active FDA-designated shortage, licensed 503A compounding pharmacies may legally compound tirzepatide with a valid prescription from a licensed clinician. Outside of a declared shortage, that pathway closes for 503A pharmacies. Legality is shortage-status-dependent, not a permanent yes or no.
What happens if the tirzepatide shortage ends?
If the FDA formally closes the shortage, 503A compounding pharmacies must stop compounding tirzepatide for general use. Patients who were on compounded tirzepatide would need to transition to branded Mounjaro or Zepbound, or work with their clinician to explore other options within legal channels.
Can a doctor still prescribe compounded tirzepatide?
A licensed clinician can prescribe compounded tirzepatide only when an FDA-designated shortage of the branded product exists and when the compounding pharmacy is a licensed 503A facility. This is a regulatory question that depends on shortage status at the time of the prescription.
Is compounded tirzepatide the same as Mounjaro or Zepbound?
Compounded tirzepatide contains the same active ingredient (tirzepatide) as branded Mounjaro and Zepbound, but compounded products are not FDA-approved drugs and are not manufactured by Eli Lilly. They are prepared by licensed 503A pharmacies under a physician's prescription from bulk drug substances. PepScribe only works with licensed 503A pharmacies in the USA — no overseas sourcing.
What should I do if my compounded tirzepatide access changes?
Talk to a licensed clinician before making any changes. Depending on your situation and goals, options may include transitioning to a branded product, adjusting dose, or discussing other clinician-supervised approaches. Do not abruptly stop a GLP-1 agonist without medical guidance.